Literature DB >> 34162727

Meningeal B Cell Clusters Correlate with Submeningeal Pathology in a Natural Model of Multiple Sclerosis.

Molly E Church1, Guadalupe Ceja1, Megan McGeehan1, Miles C Miller1, Priscilla Farias1, Melissa D Sánchez1, Gary P Swain2, Charles-Antoine Assenmacher1, Edward G Stopa3, Charles H Vite2, Amit Bar-Or4, Jorge I Alvarez5.   

Abstract

Multiple sclerosis (MS) is an idiopathic demyelinating disease in which meningeal inflammation correlates with accelerated disease progression. The study of meningeal inflammation in MS has been limited because of constrained access to MS brain/spinal cord specimens and the lack of experimental models recapitulating progressive MS. Unlike induced models, a spontaneously occurring model would offer a unique opportunity to understand MS immunopathogenesis and provide a compelling framework for translational research. We propose granulomatous meningoencephalomyelitis (GME) as a natural model to study neuropathological aspects of MS. GME is an idiopathic, progressive neuroinflammatory disease of young dogs with a female bias. In the GME cases examined in this study, the meninges displayed focal and disseminated leptomeningeal enhancement on magnetic resonance imaging, which correlated with heavy leptomeningeal lymphocytic infiltration. These leptomeningeal infiltrates resembled tertiary lymphoid organs containing large B cell clusters that included few proliferating Ki67+ cells, plasma cells, follicular dendritic/reticular cells, and germinal center B cell-like cells. These B cell collections were confined in a specialized network of collagen fibers associated with the expression of the lympho-organogenic chemokines CXCL13 and CCL21. Although neuroparenchymal perivascular infiltrates contained B cells, they lacked the immune signature of aggregates in the meningeal compartment. Finally, meningeal B cell accumulation correlated significantly with cortical demyelination reflecting neuropathological similarities to MS. Hence, during chronic neuroinflammation, the meningeal microenvironment sustains B cell accumulation that is accompanied by underlying neuroparenchymal injury, indicating GME as a novel, naturally occurring model to study compartmentalized neuroinflammation and the associated pathology thought to contribute to progressive MS.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 34162727      PMCID: PMC8695639          DOI: 10.4049/jimmunol.2000514

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  115 in total

1.  Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions.

Authors:  Jorge Ivan Alvarez; Olivia Saint-Laurent; Alisha Godschalk; Simone Terouz; Casper Briels; Sandra Larouche; Lyne Bourbonnière; Catherine Larochelle; Alexandre Prat
Journal:  Neurobiol Dis       Date:  2014-11-01       Impact factor: 5.996

2.  Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation.

Authors:  Natalia B Pikor; Jillian L Astarita; Leslie Summers-Deluca; Georgina Galicia; Joy Qu; Lesley A Ward; Susan Armstrong; Claudia X Dominguez; Deepali Malhotra; Brendan Heiden; Robert Kay; Valera Castanov; Hanane Touil; Louis Boon; Paul O'Connor; Amit Bar-Or; Alexandre Prat; Valeria Ramaglia; Samuel Ludwin; Shannon J Turley; Jennifer L Gommerman
Journal:  Immunity       Date:  2015-12-15       Impact factor: 31.745

3.  Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.

Authors:  Martina Absinta; Luisa Vuolo; Anuradha Rao; Govind Nair; Pascal Sati; Irene C M Cortese; Joan Ohayon; Kaylan Fenton; María I Reyes-Mantilla; Dragan Maric; Peter A Calabresi; John A Butman; Carlos A Pardo; Daniel S Reich
Journal:  Neurology       Date:  2015-04-17       Impact factor: 9.910

Review 4.  Improving human cancer therapy through the evaluation of pet dogs.

Authors:  Amy K LeBlanc; Christina N Mazcko
Journal:  Nat Rev Cancer       Date:  2020-09-15       Impact factor: 60.716

5.  CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions.

Authors:  M Krumbholz; D Theil; F Steinmeyer; S Cepok; B Hemmer; M Hofbauer; C Farina; T Derfuss; A Junker; T Arzberger; I Sinicina; C Hartle; J Newcombe; R Hohlfeld; E Meinl
Journal:  J Neuroimmunol       Date:  2007-09-06       Impact factor: 3.478

6.  Evidence for differential changes of junctional complex proteins in murine neurocysticercosis dependent upon CNS vasculature.

Authors:  Jorge I Alvarez; Judy M Teale
Journal:  Brain Res       Date:  2007-07-14       Impact factor: 3.252

Review 7.  The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?

Authors:  Howard L Weiner
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

8.  Meningeal Infiltration of the Spinal Cord by Non-Classically Activated B Cells is Associated with Chronic Disease Course in a Spontaneous B Cell-Dependent Model of CNS Autoimmune Disease.

Authors:  Amy K Dang; Yodit Tesfagiorgis; Rajiv W Jain; Heather C Craig; Steven M Kerfoot
Journal:  Front Immunol       Date:  2015-09-15       Impact factor: 7.561

Review 9.  Involvement of CD8(+) T Cells in Multiple Sclerosis.

Authors:  Marion Salou; Bryan Nicol; Alexandra Garcia; David-Axel Laplaud
Journal:  Front Immunol       Date:  2015-11-26       Impact factor: 7.561

10.  The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells.

Authors:  Joana Machado-Santos; Etsuji Saji; Anna R Tröscher; Manuela Paunovic; Roland Liblau; Galina Gabriely; Christian G Bien; Jan Bauer; Hans Lassmann
Journal:  Brain       Date:  2018-07-01       Impact factor: 15.255

View more
  1 in total

1.  Editorial: Role of Inflammation in Neurodegenerative Diseases.

Authors:  Maya Koronyo-Hamaoui; Bhakta Prasad Gaire; Sally Ann Frautschy; Jorge Ivan Alvarez
Journal:  Front Immunol       Date:  2022-06-21       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.